ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2025.05.007
Effect of Rituximab on Immune Function in Pediatric B-cell Non-Hodgkin Lymphoma
Ruibo Zhang*, Kun Zheng, Lan Ren
Department of Pediatrics, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
*Corresponding author: Ruibo Zhang
Published: May 31,2025
Abstract
Objective: To investigate the effect of rituximab on the immune function of pediatric B-cell non-Hodgkin lymphoma. Methods: According to different treatment methods, 25 children with B-cell non-Hodgkin lymphoma collected from January 2021 to December 2023 were divided into a control group (CHOP chemotherapy, n = 13 cases) and an observation group (CHOP chemotherapy combined with rituximab, n = 12 patients). The incidence of adverse events, clinical efficacy, and immune function of the two groups were observed. Results: Before the treatment, there was no difference between the two groups (P > 0.05); before the treatment, the two groups were different, and the CD3 + and CD4 + levels of the observation group were higher than the control group, and the CD8 + level was lower than the control group (P < 0.05); the total response rate was higher than that of the observation group, and the incidence of adverse events was lower than the control group (P < 0.05). Conclusion: Treatment with rituximab in pediatric B-cell non-Hodgkin lymphoma can effectively improve the immune function of pediatric children, with significant clinical efficacy and a low incidence of adverse events during treatment.
Keywords
Pediatric B-cell non-Hodgkin lymphoma; immune function; rituximab
References
[1] Rashwan E, Ibrahim N, Salem LM. Evaluation of NFKB1 and MyD88 expression levels in a sample of non-Hodgkin lymphoma patients before and during chemotherapy. Egypt J Basic Appl Sci. 2024;11(1):386-401.
[2] Zheng Y, Chen R, Hua X, et al. Clinical features and prognostic factors of non-Hodgkin lymphoma in children with different pathological subtypes. Chin J Exp Hematol. 2020;28(2):500-6.
[3] Changhee P, Sup HL, Won KK, et al. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nat Commun. 2024;15(1):2776.
[4] Tang J. Advances in the diagnosis and treatment of common tumors in children. Chin J Pediatr Blood Oncol. 2020;25(6):313-5.
[5] Yang X, Liu T, Wang X, et al. Clinical features and prognosis of mature B cell non-Hodgkin lymphoma with gastrointestinal perforation in children. Chin Med J. 2024;104(27):2568-71.
[6] Lake K, Jackson M, All S, et al. Ultra-low-dose adaptive radiotherapy and single-agent rituximab for indolent non-Hodgkin lymphomas: where less is more in combined modality therapy. Int J Radiat Oncol Biol Phys. 2024;120(2):635-6.
[7] Tetsuya M, Tomoo O, Akiko K, et al. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: a report from the JPLSG B-NHL14 trial. Eur J Haematol. 2023;112(4):585-93.
[8] Chen Z, Yi T, Tan B. Efficacy of rituximab combined with CHOP regimen in treating B-cell non-Hodgkin's lymphoma. Chin J Clin Oncol Rehabil. 2022;29(1):48-50.
How to cite this paper
Effect of Rituximab on Immune Function in Pediatric B-cell Non-Hodgkin Lymphoma
How to cite this paper: Ruibo Zhang, Kun Zheng, Lan Ren. (2025) Effect of Rituximab on Immune Function in Pediatric B-cell Non-Hodgkin Lymphoma. International Journal of Clinical and Experimental Medicine Research, 9(3), 295-298.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.05.007